Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand

Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand

Abstract Background Non-alcoholic steatohepatitis (NASH) has been recognised as a significant form of chronic liver disease and a common cause of cirrhosis and hepatocellular carcinoma, resulting in a considerable financial burden on healthcare resources. Currently, there is no information regarding...

Full description

Bibliographic Details
Main Authors:	Pochamana Phisalprapa, Ratthanon Prasitwarachot, Chayanis Kositamongkol, Pranaidej Hengswat, Weerachai Srivanichakorn, Chaiwat Washirasaksiri, Sombat Treeprasertsuk, Phunchai Charatcharoenwitthaya, Nathorn Chaiyakunapruk
Format:	Article
Language:	English
Published:	BMC 2021-03-01
Series:	BMC Gastroenterology
Subjects:	Non-alcoholic steatohepatitis NASH Significant fibrosis Economic burden Cost of illness Prevalence
Online Access:	https://doi.org/10.1186/s12876-021-01720-w

Similar Items

Beverage consumption in patients with metabolic syndrome and its association with non-alcoholic fatty liver disease: a cross-sectional study
by: Chayanis Kositamongkol, et al.
Published: (2024-01-01)

Effects of Synbiotics, Probiotics, and Prebiotics on Liver Enzymes of Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis
by: Sukrit Kanchanasurakit, et al.
Published: (2022-05-01)

Clinical Predictive Score for Identifying Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals with Prediabetes Using Transient Elastography
by: Nutthachoke Mahachai, et al.
Published: (2023-12-01)

Accuracy and the factors influencing the accuracy of death certificates completed by first-year general practitioners in Thailand
by: Chaiwat Washirasaksiri, et al.
Published: (2018-06-01)

Pathohistological characteristics of steatohepatitis on needle biopsy sample from 100 patients
by: Milićević Anđela, et al.
Published: (2019-01-01)

Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis
by: Ćulafić Milica, et al.
Published: (2020-01-01)

Long-Term Outcomes Associated with NAFLD, ASCVD, and All-Cause Mortality of Patients with Metabolic Syndrome
by: Suchanart Jitrukthai, et al.
Published: (2022-08-01)

Clinical Differences and Non-Alcoholic Fatty Liver Disease-Related Factors of Lean and Non-Lean Patients with Metabolic Syndrome
by: Punyisa Boonchai, et al.
Published: (2022-04-01)

Vitamin D Status and Steatohepatitis in Obese Diabetic and Non-Diabetic Patients
by: Laura Taban, et al.
Published: (2022-09-01)

The burden of carbapenem-resistant Enterobacterales infection in a large Thai tertiary care hospital
by: Watcharaphon Tangsawad, et al.
Published: (2022-09-01)

Fasting plasma glucose and HbA1c levels predict the risk of type 2 diabetes and diabetic retinopathy in a Thai high-risk population with prediabetes
by: Chaiwat Washirasaksiri, et al.
Published: (2022-10-01)

Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity
by: Joseph L. Jilek, et al.
Published: (2021-12-01)

Angiogenic effects of leptin in patients with nonalcoholic steatohepatitis
by: Gaafar Nagah, et al.
Published: (2005-01-01)

Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome
by: Martha D. Gay, et al.
Published: (2022-02-01)

Double Trouble: How Microbiome Dysbiosis and Mitochondrial Dysfunction Drive Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
by: Wesam Bahitham, et al.
Published: (2024-02-01)

Nonalcoholic steatohepatitis: global impact and clinical consequences
by: Khaled Kabarra, et al.
Published: (2021-10-01)

Non-Alcoholic Steatohepatitis Decreases Microsomal Liver Function in the Absence of Fibrosis
by: Wim Verlinden, et al.
Published: (2020-11-01)

The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes
by: Zobair Younossi, et al.
Published: (2022-09-01)

Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis: A systematic review and meta-analysis
by: Adam Minich, et al.
Published: (2022-08-01)

Cost–Utility and Budget Impact Analyses of Oral Chemotherapy for Stage III Colorectal Cancer: Real-World Evidence after Policy Implementation in Thailand
by: Pochamana Phisalprapa, et al.
Published: (2023-10-01)

Elastographic liver evaluation of Katukyadi churna in the management of Non-Alcoholic Steatohepatitis (NASH) – A single arm clinical trial.
by: Shruti Tarapure, et al.
Published: (2021-01-01)

Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review
by: Tessa Kennedy-Martin, et al.
Published: (2018-06-01)

Beneficial effects of ginkgetin on improving nonalcoholic steatohepatitis characterized by bulk and single-cell RNA sequencing analysis
by: Chaoyang Wang, et al.
Published: (2023-10-01)

Nonobese mice with nonalcoholic steatohepatitis fed on a choline‐deficient, l‐amino acid‐defined, high‐fat diet exhibit alterations in signaling pathways
by: Noriko Suzuki‐Kemuriyama, et al.
Published: (2021-11-01)

Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western DietSummary
by: Souradipta Ganguly, et al.
Published: (2021-01-01)

Hepatic transcriptome profiling reveals early signatures associated with disease transition from non-alcoholic steatosis to steatohepatitis
by: Nancy Magee, et al.
Published: (2022-12-01)

Alcohol or Not: A Review Comparing Initial Mechanisms, Contributing Factors, and Liver Transplantation Outcomes Between Alcoholic and Nonalcoholic Steatohepatitis
by: Chung-Shiung Wen, et al.
Published: (2018-09-01)

Qushi Huayu decoction attenuated hepatic lipid accumulation via JAK2/STAT3/CPT-1A-related fatty acid β-oxidation in mice with non-alcoholic steatohepatitis
by: QinMei Sun, et al.
Published: (2022-12-01)

Study of Cytochrome P450 2E1 and its allele Variants in Liver Injury of Nondiabetic, Nonalcoholic Steatohepatitis Obese Women
by: NELSON M VARELA, et al.
Published: (2008-01-01)

A simple method for inducing nonalcoholic steatohepatitis with fibrosis
by: Leyla Yahaghi, et al.
Published: (2019-12-01)

Non-alcoholic fatty liver disease as a risk factor for cholangiocarcinoma: a systematic review and meta-analysis
by: Nicha Wongjarupong, et al.
Published: (2017-12-01)

FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trialResearch in context
by: Vincent Wai-Sun Wong, et al.
Published: (2023-12-01)

Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH)
by: Xiaoyan Qi, et al.
Published: (2022-11-01)

Editorial: Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
by: Ana Sandoval-Rodriguez, et al.
Published: (2022-04-01)

L-Selectin/CD62L Is a Key Driver of Non-Alcoholic Steatohepatitis in Mice and Men
by: Hannah K. Drescher, et al.
Published: (2020-04-01)

Clinicopathologic features of de novo non-alcoholic steatohepatitis in the post-transplant setting
by: Dana Balitzer, et al.
Published: (2022-08-01)

Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH)
by: Jin Ha Lee, et al.
Published: (2020-10-01)

Chemotherapy-associated steatohepatitis
by: Lucy Meunier, et al.
Published: (2020-11-01)

Presence and Implications of Sarcopenia in Non-alcoholic Steatohepatitis
by: Gregory Habig, et al.
Published: (2021-04-01)

CD47 Deficiency in Mice Exacerbates Chronic Fatty Diet-Induced Steatohepatitis Through Its Role in Regulating Hepatic Inflammation and Lipid Metabolism
by: Hui-Chao Tao, et al.
Published: (2020-02-01)